At Tegmine, we believe that better targets make better therapies. We find targets that others can’t. Our discovery platform uses a mix of biology, mass spectrometry, and machine learning to unlock protein targets in their disease-state. Starting in oncology with solid tumors, Tegmine is developing the next generation of antibody drug targets, which are more specific to the tumor, sparing normal healthy tissues. Better targets. Better therapies.

Corporate Address

4104 24th St., Suite PMB 405

San Francisco, CA 94114

Research Center

329 Oyster Point Blvd.

3rd Floor

South San Francisco, CA 94080